» Articles » PMID: 16202458

Trypanosome Lytic Factor, a Subclass of High-density Lipoprotein, Forms Cation-selective Pores in Membranes

Overview
Date 2005 Oct 6
PMID 16202458
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Trypanosome lytic factor 1 (TLF1) is a subclass of human high-density lipoprotein that kills some African trypanosomes thereby protecting humans from infection. We have shown that TLF1 is a 500 kDa HDL complex composed of lipids and at least seven different proteins. Here we present evidence outlining a new paradigm for the mechanism of lysis; TLF1 forms cation-selective pores in membranes. We show that the replacement of external Na+ (23 Da) with the larger tetramethylammonium+, choline+ and tetraethylammonium+ ions (74 Da, 104 Da and 130 Da) ameliorates the osmotically driven swelling and lysis of trypanosomes by TLF1. Confirmation of cation pore-formation was obtained using small unilamellar vesicles incubated with TLF1; these showed the predicted change in membrane potential expected from an influx of sodium ions. Using planar lipid bilayer model membranes made from trypanosome lipids, which allow the detection of single channels, we found that TLF1 forms discrete ion-conducting channels (17 pS) that are selective for potassium ions over chloride ions. We propose that the initial influx of extracellular Na+ down its concentration gradient promotes the passive entry of Cl- through preexisting Cl- channels. The net influx of both Na+ and Cl- create an osmotic imbalance that leads to passive water diffusion. This loss of osmoregulation results in cytoplasmic vacuolization, cell swelling and ultimately trypanosome lysis.

Citing Articles

Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies.

Afsar B, Afsar R, Caliskan Y, Lentine K Int Urol Nephrol. 2025; .

PMID: 40038200 DOI: 10.1007/s11255-025-04443-z.


Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.


Apolipoprotein-L1 (APOL1): From Sleeping Sickness to Kidney Disease.

Pays E Cells. 2024; 13(20.

PMID: 39451256 PMC: 11506758. DOI: 10.3390/cells13201738.


APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.

Datta S, Antonio B, Zahler N, Theile J, Krafte D, Zhang H J Clin Invest. 2024; 134(5).

PMID: 38227370 PMC: 10904047. DOI: 10.1172/JCI172262.


Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.

Vandorpe D, Heneghan J, Waitzman J, McCarthy G, Blasio A, Magraner J Pflugers Arch. 2022; 475(3):323-341.

PMID: 36449077 PMC: 10321438. DOI: 10.1007/s00424-022-02767-8.